EDG-5506-201

Recruiting

99 years and younger

All

Phase N/A

1 Location

Brief description of study

This is a multicenter, randomized, Phase 2, double-blind, placebo-controlled study to evaluate the effect of EDG-5506 on the safety, PK, biomarkers, and functional measures in adult and adolescent participants with BMD. This randomized, double-blind, placebo-controlled study will evaluate the safety, pharmacokinetics (PK), and efficacy of EDG-5506 in adults and adolescents with genetically confirmed BMD.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Medical Research
Age: - 99 Years
Gender: All

TBD

Updated on 09 Mar 2024. Study ID: 853514

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).